Two Onc Docs
Localized Breast Cancer 2024 UPDATE
Oct 14, 2024
Dr. Eleonora Teplinsky, a board-certified medical oncologist specializing in breast and gynecologic oncology, brings her expertise on localized breast cancer treatment. She discusses groundbreaking updates on radiation therapies and the nuances of ER/PR/HER2 receptor-based treatments. Topics include personalized chemotherapy approaches, the APT trial for HER2 positive cancer, and effective hormone treatments tailored to patient profiles. Dr. Teplinsky also delves into chemotherapy regimens suitable for pregnant patients, emphasizing individualized care strategies.
28:49
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Tailored treatment for localized breast cancer heavily relies on receptor status, distinguishing between estrogen/progesterone positive, HER2 positive, and triple-negative subtypes.
- Recent strategies advocate for de-escalating therapy in older patients with lower-risk tumors, allowing some to forgo radiation post-lumpectomy.
Deep dives
Understanding Breast Cancer Subtypes
Localized breast cancer treatment varies significantly based on receptor status, with 70-80% of cases being estrogen or progesterone positive, and 15-20% HER2 positive. Triple-negative breast cancer constitutes the remaining 15-20% and often necessitates chemotherapy for all patients. For stage two and three triple-negative cases, immunotherapy has been added to the standard chemotherapy regimen, improving survival rates. These distinctions in receptor positivity guide treatment plans and therapeutic approaches, emphasizing the importance of categorizing breast cancer subtypes for effective intervention.
